BEN-301 / Bennu Biotherap - LARVOL DELTA

A Study of BEN301 Injection in theTreatment of Autoimmune Diseases (clinicaltrials.gov) - P1 | N=24 | Suspended | Sponsor: RenJi Hospital | Not yet recruiting ➔ Suspended

Trial suspension • Immunology • Inflammatory Arthritis • Myositis • Rheumatoid Arthritis • Rheumatology • Scleroderma • Sjogren's Syndrome • Systemic Sclerosis • CRP

CD19 Targeted Chimeric Antigen Receptor (CAR)-Regulatory T Cells (BEN301): Preclinical Efficacy and Safety for Autoimmune Diseases (ASGCT 2026) - "Our preclinical data confirmed the robust efficacy of BEN301 in resetting immune tolerance in SLE models and a favorable safety profile. These findings strongly support advancing BEN301 to clinical trials to evaluate its safety and efficacy in AIDs patients, potentially providing a transformative therapy for severe autoimmune diseases."

IO biomarker • Preclinical • Hematological Disorders • Immunology • Infectious Disease • Inflammatory Arthritis • CTLA4 • FOXP3 • IFNG • IL2RA • IL6 • TGFB1 • TNFA

A Study of BEN301 Injection in theTreatment of Autoimmune Diseases (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: RenJi Hospital

New P1 trial • Immunology • Inflammatory Arthritis • Myositis • Rheumatoid Arthritis • Rheumatology • Scleroderma • Sjogren's Syndrome • Systemic Sclerosis • CRP

A Phase I Study of BEN301 Injection in the Treatment of Autoimmune Diseases (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: Beijing Boren Hospital

New P1 trial • Immunology • CRP